$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Gastroenterology
Gastroenterology
埃索美拉唑治疗效果怎么样?
2025-10-19 11:44:20
Check Details
埃索美拉唑可治疗什么病症呢?
2025-10-19 11:44:20
Check Details
耐信说明书
2025-10-19 11:44:20
Check Details
耐信注意事项
2025-10-19 11:44:20
Check Details
耐信进医保了没?
2025-10-19 11:44:20
Check Details
耐信使用量多少?
2025-10-19 11:44:20
Check Details
耐信用法用量
2025-10-19 11:44:20
Check Details
耐信适应症
2025-10-19 11:44:20
Check Details
耐信上市了吗?
2025-10-19 11:44:20
Check Details
耐信治疗效果怎么样?
2025-10-19 11:44:20
Check Details
耐信适用于治疗什么病症?
2025-10-19 11:44:20
Check Details
耐信作用功效
2025-10-19 11:44:20
Check Details
1
2
...
29
30
31
32
33
34
35
...
57
58
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits
2
Ramosetron ODT for IBS-D: Gender-Based Dosing and Treatment Review
3
Obeticholic Acid 5 mg for PBC: Dosage, Risks, and Current Status
4
Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer: FDA Accelerated Approval and AZUR-1
5
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
6
Lusutrombopag Safety and Dosing: Thrombosis Risk and Indications
7
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
8
Filgotinib: Mechanism of Action and Clinical Applications Explained
9
Elafibranor for Primary Biliary Cholangitis: Indication, Dosing, and Safety Overview
10
Lusutrombopag: An Oral Pre-procedural Option for Thrombocytopenia in Chronic Liver Disease
11
Lusutrombopag: Complete Guide to Dosage, Administration and Clinical Monitoring
12
Resmetirom (Rezdiffra) Safety Guide: Hepatotoxicity, Gallbladder Risks & Statin Interactions Explained